J. Sevigny

发表

Review: Item Analysis of ADAS-Cog: Effect of Baseline Cognitive Impairment in a Clinical AD Trial

J. Sevigny, Yahong Peng, Lian Liu, 2010, American journal of Alzheimer's disease and other dementias.

An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.

K. Marder, Y. Stern, J. Sevigny, 2007, Archives of neurology.

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia

K. Marder, Y. Stern, J. Sevigny, 2004, Neurology.

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial

J. Sevigny, J. Suhy, M. Sampat, 2016, Alzheimer disease and associated disorders.

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2016, Nature.

Patients with autism spectrum disorders display reproducible functional connectivity alterations

Garry D. Honey, Joerg F. Hipp, Tony Charman, 2019, Science Translational Medicine.

Early risk assessment for Alzheimer's disease

M. Carrillo, J. Sevigny, W. Klunk, 2009, Alzheimer's & Dementia.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2017, Nature.

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects

James Robert Brašić, M. Albert, C. Lyketsos, 2018, The Journal of Nuclear Medicine.

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

Norbert Schuff, Arthur W. Toga, John Seibyl, 2018, Annals of clinical and translational neurology.

Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations

J. Sevigny, A. Abeliovich, F. Hefti, 2021, Journal of Parkinson's disease.

Extracorporeal treatment of thrombotic microangiopathy: a ten year experience.

J. Sevigny, A. Kaplan, D. Bueno, 1999, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

Current state of Alzheimer’s fluid biomarkers

José Luis Molinuevo, Harald Hampel, Leslie M. Shaw, 2018, Acta Neuropathologica.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Merit Cudkowicz, Shiyang Ma, E Ray Dorsey, 2017, Neurology.

One year's experience using a rotating filter for therapeutic plasma exchange.

J. Sevigny, A. Kaplan, S. Halley, 1989, ASAIO transactions.

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

J. Sevigny, J. O’Gorman, Alvydas Mikulskis, 2016, Alzheimer's & dementia.

Angiostrongylus cantonensismeningitis presenting with facial nerve palsy

J. Sevigny, R. Gupta, E. Furuya, 2004, Journal of Neurology.

Angiostrongylus cantonensis meningitis presenting with facial nerve palsy.

J. Sevigny, D. Podwall, E. Furuya, 2004, Journal of Neurology.

Reproducible functional connectivity alterations are associated with autism spectrum disorder

Christopher H. Chatham, R. Delorme, M. Leboyer, 2018, bioRxiv.

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

J. Sevigny, P. Fontoura, D. Umbricht, 2019, Science Translational Medicine.

Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II

Christopher H. Chatham, T. Charman, E. Loth, 2018, Autism research : official journal of the International Society for Autism Research.

6th Conference Clinical Trials on Alzheimer’s Disease ABSTRACTS November 14–16, 2013 San Diego, CA — USA

S., G. Jicha, J. Sevigny, 2013, The journal of nutrition, health & aging.

Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study

Roger M. Nitsch, Leslie Williams, Ping Chiao, 2015, Alzheimer's & Dementia.

Optimizing Central Nervous System Drug Development Using Molecular Imaging

J. Sevigny, J. Hoppin, P. Chiao, 2015, Clinical pharmacology and therapeutics.

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

W. Poewe, J. Sevigny, R. Doody, 2021, Frontiers in Neurology.

Growth hormone secretagogue MK-677

J. Sevigny, C. V. van Dyck, M. Nessly, 2008, Neurology.

Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003)

F. Barkhof, M. Sano, S. Salloway, 2016 .

Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients

B. Winblad, J. Sevigny, N. Andreasen, 2010, Alzheimer's & Dementia.

Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms

Christopher H. Chatham, M. Frank, J. Dukart, 2021, Biological psychiatry global open science.

Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch: A Post-hoc Analysis of a Double-blind Trial in Patients With Alzheimer Disease

J. Sevigny, Jae-Hong Lee, 2011, Alzheimer disease and associated disorders.

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects

James Robert Brašić, M. Albert, C. Lyketsos, 2018, The Journal of Nuclear Medicine.

progression in a randomized trial Growth hormone secretagogue MK-677 : No clinical effect on AD

J. Sevigny, C. Dyck, Y. Peng, 2008 .